X

Trial Profile

Safety, tolerability and pharmacokinetics of siponimod in combination with CYP2C9/3A4 inducer, rifampin in healthy volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 20 Aug 2018

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Siponimod (Primary) ; Rifampicin
Indications Dermatomyositis; Multiple sclerosis; Polymyositis
Focus Pharmacokinetics

Most Recent Events

13 Aug 2018 Results published in the European Journal of Clinical Pharmacology
21 Nov 2017 New trial record
28 Oct 2017 Results presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com